- Home
- ADEA vs SPRY Comparison
ADEA vs SPRY Comparison
Compare ADEA & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADEA
- SPRY
- Stock Information
- Founded
- ADEA 1990
- SPRY 2015
- Country
- ADEA United States
- SPRY United States
- Employees
- ADEA N/A
- SPRY N/A
- Industry
- ADEA Computer Software: Prepackaged Software
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- ADEA Technology
- SPRY Health Care
- Exchange
- ADEA Nasdaq
- SPRY Nasdaq
- Market Cap
- ADEA 1.5B
- SPRY 1.4B
- IPO Year
- ADEA N/A
- SPRY N/A
- Fundamental
- Price
- ADEA $13.74
- SPRY $15.69
- Analyst Decision
- ADEA Strong Buy
- SPRY Strong Buy
- Analyst Count
- ADEA 4
- SPRY 4
- Target Price
- ADEA $19.50
- SPRY $28.75
- AVG Volume (30 Days)
- ADEA 445.3K
- SPRY 1.2M
- Earning Date
- ADEA 08-05-2025
- SPRY 08-05-2025
- Dividend Yield
- ADEA 1.45%
- SPRY N/A
- EPS Growth
- ADEA 89.09
- SPRY N/A
- EPS
- ADEA 0.66
- SPRY N/A
- Revenue
- ADEA $380,289,000.00
- SPRY $97,122,000.00
- Revenue This Year
- ADEA $10.68
- SPRY N/A
- Revenue Next Year
- ADEA $4.16
- SPRY $140.40
- P/E Ratio
- ADEA $20.93
- SPRY N/A
- Revenue Growth
- ADEA 7.16
- SPRY 971120.00
- 52 Week Low
- ADEA $9.68
- SPRY $7.55
- 52 Week High
- ADEA $17.46
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- ADEA 57.90
- SPRY 60.81
- Support Level
- ADEA $12.96
- SPRY $14.77
- Resistance Level
- ADEA $14.20
- SPRY $16.23
- Average True Range (ATR)
- ADEA 0.39
- SPRY 0.73
- MACD
- ADEA -0.01
- SPRY 0.12
- Stochastic Oscillator
- ADEA 70.42
- SPRY 84.68
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, it primarily license innovations to leading companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.